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complement RCT data and prospective patient registries for the evaluation of con-
temporary practice including biomarkers used for diagnosis, treatment decisions
and prognosis in the management of CML patients.
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OBJECTIVES: The consideration of subgroup analyses is an emerging topic in
health care evaluation. With value-for-money being an important issue, alongside
the question “is this therapy effective?”, another question becomingmore relevant
is “in whom is this therapy effective?” This issue is particularly relevant to the
development of cancer treatments, which are often expensive and indicated in
small patient populations. The use of personalised medicine is therefore expected
to play a large role in this disease area. The aimof this studywas to investigate how
the proportion of cancer trials taking personalised medicine into account has
changed over time. METHODS: ClinicalTrials.gov was searched for all interven-
tional cancer trials that considered the use of individualised medicine, by using
search terms including ‘diagnostic’, ‘prognostic’ and ‘biomarker’. Search results
were de-duplicated, and the start dates of these trialswere analysed and compared
to those of all interventional cancer trials listed on ClinicalTrials.gov. RESULTS: In
total, 2810 cancer trials considered personalised medicine. The distribution of
thesewas strongly skewed towards recent years,with only 57 of the trials identified
having started before 2000. Across all cancer trials, 2.5%of those started before 2000
considered personalised medicine, whereas this percentage increased to 13.6%
after this date. Interestingly, 20.6% of cancer trials commencing in 2010, compared
to 17.0% of those in 2011, involved individualised medicine, indicating that there
might be a slight decline in the investigation of personalised medicine recently.
Trials considering individualised medicine were most often conducted in the
United States or Europe, and in disease areas such as leukaemia, head and neck,
brain, and prostate cancer. CONCLUSIONS: Personalised medicine has started to
play a bigger role in cancer therapy development since the year 2000. With the
current health care market focusing on value-for-money, however, it is surprising
that only one-fifth of recent trials considered this issue.
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OBJECTIVES:Using a simplemethodwe determined the potential transferability of
a previous economic evaluation on the cost effectiveness of adjuvant trastuzumab
therapy for the treatment ofHER2/Neu-positive breast cancer in Canada (Skedgel et
al, 2009) to five other countries (UK, US, Australia, Japan and Germany).METHODS:
Based on data from a literature review, we firstly identified all possible transfer-
ability factors. From this we selected key transferability factors – those with values
that differed across the countries or were factors that were shown to influence the
cost-effectiveness ratio in sensitivity analysis in the Canadian reference study.We
then considered the ease of transferability (ranging from very low to very high) for
each of these potential factors from the Canadian study to the other countries.
RESULTS: We identified seven potential key factors for transferability: cost dis-
count rate, health outcomes discount rate, unit costs (particularly drug acquisition
cost), resources used, treatment effectiveness, (including duration of benefit) and
measures used to determine utility values. Overall, potential transferability was
highest for the UK, where treatment practice is similar to that in Canada and data
on unit costs, resource use and discount rates are readily available. Because the
authors of the reference study did not report unit costs and resource use sepa-
rately, however, transferability of the analysis was hindered. Transferability to
Australia, Germany and the United States was of an intermediate level, while
transferability to the Japanese settingwas the lowest because treatment practice is
likely to be different, and little cost of illness and utility data exist for that country.
CONCLUSIONS: Several key factors need to be considered when evaluating
whether a study is transferable to another setting. To enable the transferability of
economic evaluations from one country to another, authors need to ensure that
they report their economic data clearly and in sufficient detail.
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OBJECTIVES: Pooling annual data together from the Medical Expenditure Panel
Survey (MEPS) is legitimate way to produce average annual estimates based on
“person-years” for any condition. AHRQ state that over 100 cases are required in
order to do this. The objective of this study is to look at the direct medical costs
associated with head and neck cancer (HNC) using this data source. METHODS:
MEPS data was pooled (2003-2008) and analyzed for respondents with HNC (CCS
code11). Two different approaches were used. Consolidated year files and condi-
tion files were pooled together to calculate estimates on use and expenditures for
persons with HNC (condition approach). Yearly event files were used to pool con-
dition-event files to establish an attributable fraction approach. Both approaches
inflated expenditure data to 2008 USD. RESULTS: A total of 120 respondents were
identified to have a diagnosis of HNC when data was pooled. The condition ap-
proach estimated that the national yearly expenditures of HNC is in the order of
$16.47bn with mean spend of $14,573 (SE$2,227) per case per year. The attribut-
able fraction approach estimated that expenditures for all events associated with
HNC are significantly less - $8.49bn with a mean of $4788 (SE$1,057) per case per
year. There were only 103 cases that had an event associated with the condition.
Private payors accounted formost expenditure, though the proportionwas slightly
lower using the condition approach (46% vs. 56%). The analysis noted that attrib-
utable expenditures were driven by ambulatory visits where condition expendi-
tures were driven by inpatient costs. CONCLUSIONS: MEPS is often used to esti-
mate the direct medical costs of a condition. This analysis illustrates that for rare
cases, such as HNC, that both approaches offer insight into characterizing a con-
dition. Subsequently, a range for cost estimates can be determined using this data
source.
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OBJECTIVES: Determining which economic and health resource utilization data
points to collect in clinical trials requires a balance between comprehensiveness
and data collection burden. Cost and time constraints necessitate that only the
most critical economic variables be collected. Our objectivewas to test the utility of
a new tool for determining the most frequent types and timing of healthcare uti-
lization among cancer patients in a quick and low cost manner. METHODS: We
used an online interactive data analysis tool, MarketScan®Treatment Pathways, to
explore the most frequent adverse events (AE) and their related healthcare utiliza-
tion patterns in a sample of non-small cell cancer patients (NSCLC). Patientswith at
least 2 ICD-9 codes for lung cancer on different dayswithin 30 days of each other on
non-rule out claims and no chemotherapies associatedwith small-cell lung cancer
were included. The subset of patients with a diagnosis for metastatic cancer fol-
lowing their NSCLC diagnosis who received at least one oral or injectible chemo-
therapy treatment were analyzed. RESULTS: 5,243 patients withmetastatic NSCLC
were identified, of whom 2,006 received at least one oral or injectible treatment.
80% of experienced at least one AE serious enough to require healthcare interven-
tion. Themedian andmean days to the first AEwere 20 and 51.5 days from the time
of the first treatment. Themost commonAEswere anemia (51.2%), gastrointestinal
events (34.8%), fatigue (26.1%), and neutropenia (24.2%). Of those with anemia, 36%
received epoetin or darbepoetin alpha and of thosewith neutropenia, 77% received
pegfilgrastim or filgrastim. Additional patient clinical and treatment characteris-
tics were described for the 30 days following each AE. Total analysis time for this
project was under 3 hours. CONCLUSIONS: Treatment Pathways answered critical
questions for the design of economic endpoint data collection for a new cancer trial
in just a few hours.
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OBJECTIVES: To assess the societal value of a prospective randomized clinical trial
(RCT) for breast tumor marker testing in routine follow-up of high-risk, stage II-III
breast cancer survivors. METHODS: We used value of information techniques to
assess the benefits of reducing uncertainty of using breast cancer tumor markers.
We developed a decision-analytic model of biomarker testing in addition to stan-
dard surveillance at follow-up appointments every 3-6 months for five years. Ex-
pected value of sample information (EVSI) was assessed over a range of trial sizes
and assumptions. RESULTS: The overall value of research for an RCT involving
9000 women was $166 million (EVSI). The value of improved information charac-
terizing the survival impact of tumor markers was $81 million, quality-of-life $38
million, and test performance $95 million. CONCLUSIONS: Despite not being rec-
ommended by clinical guidelines, the tumor markers carcinoembryonic antigen
(CEA), cancer antigen (CA)15-3, and CA 27.29 are used by some clinicians to screen
for increased risk of breast cancer recurrence. Although additional researchmay be
warranted to evaluate the benefits and risks of breast cancer tumor marker tests,
clinical trials would likely need to involve thousands of women and would take
many years to complete. Our analysis indicates that substantial societal valuemay
be gained by conducting a clinical trial evaluating the use of breast cancer tumor
markers. The most important aspects of the trial in our analysis were information
gained on survival improvements as well as quality-of-life parameters associated
with testing and test sensitivity and specificity. Our analysis indicates that smaller
randomized trials, as well as adding quality of life instruments to existing trials,
retrospective, and observational trials can also generate valuable and relevant in-
formation.
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